#United States #San Diego #oral biologics #Aizen Therapeutics #San Diego Biopharma

Aizen Therapeutics Partners with San Diego Biopharma

Aizen Therapeutics, a biotechnology company that harnesses AI technology, has unveiled a significant multi-program collaboration with a public biopharma firm based in San Diego. This partnership aims to develop innovative oral peptide therapeutics utilizing Aizen's proprietary DaX™ foundation model. The deal is poised to generate initial revenue in the millions and offers the potential for up to $100 million in milestone payments for each target identified.

The therapeutic promise of oral biologics is considerable, as Aizen's CEO, Ajay Kshatriya, explains: "Oral biologics represent a new frontier in drug development. We are focused on designing oral peptides for validated biological targets that can deliver an improved therapeutic index, reduced systemic toxicity, and enhanced target engagement in a pill." This collaboration highlights Aizen's commitment to partnering with leaders in the biopharmaceutical industry to develop effective therapies for significant health conditions in immunology and neurology.

The foundation of Aizen's approach lies in its cutting-edge computational design model for peptides. The DaX platform, developed by Caltech faculty, has processed millions of meticulously annotated molecules and receptors, which significantly enhances the exploration of non-canonical amino acid (ncAA) peptide chemical space. This technology surpasses the capabilities of traditional ncAA discovery methods by a factor of ten.

Dr. David Van Valen, Aizen's Scientific Founder and a Caltech Professor, notes that de novo peptide design addresses the intricate challenges of data scarcity and chemical complexity in Drug Discovery AI. This collaboration represents a milestone not only for Aizen but also for the realm of peptide therapeutics, merging advanced AI-driven design with a premier biopharma partner.

Aizen Therapeutics was born from a vision to transform the lives of patients grappling with chronic immune disorders. By focusing on oral peptides, the company seeks to deliver therapies that are both effective and easier for patients to administer. The company operates from its San Diego headquarters, backed by venture funding to fuel its advancements.

Currently, Aizen is not only advancing its own pipeline of gut-restricted and systemic oral biologics but is also forging strategic collaborations with established biopharma entities. These partnerships leverage the power of the DaX platform to tackle high-stakes technical challenges, combining the proven precision of antibodies with the practicality of small molecules that are stable and suitable for oral delivery.

As biopharmaceutical innovations continue to pave the way for advanced therapeutic solutions, Aizen's partnership with a leading San Diego biotech promises to usher in a new wave of drug development characterized by oral delivery systems that may change the treatment landscape for several diseases. By tapping into the vast potential of AI-driven drug design, Aizen Therapeutics is at the forefront of transforming biotechnology and providing hope for patients worldwide.